Such widely applied treatment can not realize the on-demand release of insulin, leading to the poor patient compliance, and sometimes hypoglycemia, which probably results in the potential risk of brain damage or death (Alloubani et al., 2018; Kawada, 2018). This evidence concerns the gene INS and Hypoglycemia.